Eli Lil­ly joins the grow­ing ranks of Big Phar­ma play­ers man­dat­ing vac­ci­na­tions for most staffers

Last year
Pharma

No­vavax, Fu­ji­film plow ahead on Covid-19 vac­cine pro­duc­tion de­spite OWS set­back

Last year
Coronavirus
Manufacturing

Man­u­fac­tur­ing is­sues hold back dis­tri­b­u­tion of over­dose in­jec­tion; San Diego biotech triples foot­print

Last year
Manufacturing

Two da­ta fal­si­fiers sen­tenced to prison as FDA pledges to crack down on those un­der­min­ing clin­i­cal tri­als

Last year
FDA+

First gener­ic com­pe­ti­tion ar­rives for Pfiz­er's megablock­buster an­ti-smok­ing drug

Last year
Pharma
FDA+

Biden's vi­sion for drug pric­ing re­forms: Medicare ne­go­ti­a­tions, penal­ties for prices ris­ing high­er than in­fla­tion

Last year
Pharma

Sen. Rand Paul re­veals his wife bought Gilead stock in Feb­ru­ary 2020 — 16 months af­ter fil­ing dead­line

Last year
People
Pharma

FDA re­jects Fi­bro­Gen's ane­mia drug, de­mand­ing an ad­di­tion­al clin­i­cal tri­al

Last year
Pharma
FDA+

'The con­sum­mate men­tor': Bill Clin­ton, Jim Wil­son and oth­ers re­flect on Tachi Ya­mada's life and lega­cy

Last year
People
In Focus

Mod­er­na strikes a deal with Cana­da to build an mR­NA man­u­fac­tur­ing cen­ter — and it’s look­ing for more glob­al pacts just like it

Last year
Coronavirus
Manufacturing

Mod­er­na soars in­to the ranks of the world's top phar­ma play­ers, now worth 3 Re­gen­erons

Last year
Bioregnum
Pharma

Gilead joins the move­ment to man­date staff vac­ci­na­tions against Covid-19. And it looks like the rest of the in­dus­try is fol­low­ing

Last year
Pharma

For­mer BAR­DA di­rec­tor set­tles whistle­blow­er case on Trump's mis­man­age­ment of the pan­dem­ic

Last year
People
Coronavirus

ADC ex­perts at Seagen find a $2.6B HER2 gem in Chi­na that they think can go where En­her­tu, Kad­cy­la can't

Last year
Deals
China

Blue­bird forced to halt tri­als af­ter a can­cer-like case, pulls gene ther­a­pies from Eu­rope fol­low­ing pric­ing back­lash — shares slammed

Last year
R&D
Cell/Gene Tx

Philip Mor­ris bags an­oth­er biotech as bid­ding war with Car­lyle over Vec­tura deal heats up

Last year
Deals

Most Fa­vored Na­tions rule for drug pric­ing: Gone, but not for­got­ten

Last year
Pharma

Biotech grieves over Tachi’s pass­ing; $3 tril­lion mi­rage?; Sanofi has a new Pompe drug; and more

Last year
Weekly

Till­man Gern­gross steers a biotech uni­corn to Nas­daq, while an­oth­er com­pa­ny's IPO plans fiz­zle

Last year
Financing

Fed­er­al cir­cuit up­holds Te­va-Glax­o­SmithK­line de­ci­sion, land­ing an­oth­er blow to 'skin­ny' la­bels

Last year
Pharma

Drug pric­ing dis­rup­tor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm

Last year
Financing
Deals

Courts to de­cide on whether drug­mak­ers have to sup­ply dis­count­ed drugs to un­lim­it­ed con­tract phar­ma­cies

Last year
Pharma

No­vavax shares dive on yet an­oth­er stum­ble in the hunt for an EUA, with FDA de­lay as US paus­es fund­ing

Last year
FDA+

Ox­ford spin­out rais­es $113M in bid to beat Sarep­ta's Ex­ondys 51 in DMD. But will we ever know if any of the drugs work?

Last year
Financing
First page Previous page 116117118119120121122 Next page Last page